Tidal Investments LLC Buys 26,790 Shares of Becton, Dickinson and Company $BDX

Tidal Investments LLC lifted its stake in Becton, Dickinson and Company (NYSE:BDX) by 22.4% in the second quarter, HoldingsChannel reports. The institutional investor owned 146,408 shares of the medical instruments supplier’s stock after buying an additional 26,790 shares during the quarter. Tidal Investments LLC’s holdings in Becton, Dickinson and Company were worth $22,156,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Imprint Wealth LLC bought a new stake in Becton, Dickinson and Company in the third quarter valued at $25,000. SHP Wealth Management bought a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at $26,000. Meeder Asset Management Inc. boosted its stake in shares of Becton, Dickinson and Company by 152.2% in the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 102 shares in the last quarter. Main Street Group LTD acquired a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at $29,000. Finally, Bell Investment Advisors Inc bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter worth about $29,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 2.0%

Shares of NYSE BDX opened at $176.18 on Friday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $193.07. The firm’s 50-day moving average is $172.11 and its 200-day moving average is $160.53. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $48.54 billion, a PE ratio of 53.07, a price-to-earnings-growth ratio of 12.67 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period in the prior year, the business posted $3.68 earnings per share. Becton, Dickinson and Company’s revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a $1.05 dividend. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. Becton, Dickinson and Company’s dividend payout ratio is 126.51%.

Analysts Set New Price Targets

Several brokerages recently issued reports on BDX. Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a report on Monday, July 6th. Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Citigroup reaffirmed a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Royal Bank Of Canada boosted their target price on Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a report on Thursday, August 13th. Finally, TD Cowen increased their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and an average target price of $187.67.

Insider Buying and Selling

In related news, CEO Thomas Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 8,005 shares of company stock valued at $1,423,580 over the last 90 days. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD’s products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.